+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Inhalable Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon


  • 139 Pages
  • February 2024
  • Infogence Global Research
  • ID: 5669511

The trend towards developing inhalable drug delivery systems continues to grow, offering more convenient and targeted administration for various medical treatments

The Global Inhalable Drugs Market is estimated to be USD 38.38 Bn in 2023 and is expected to reach USD 54.11 Bn by 2028 growing at a CAGR of 7.11%.

  • Inhalable drugs are medications that are inhaled and are often in the form of aerosols or powders. They are intended to be inhaled into the respiratory system, where they are rapidly absorbed into the bloodstream. Asthma, chronic obstructive pulmonary disease (COPD), and allergies are typical illnesses treated with inhalable drugs.
  • The increased prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma is a major driving force in the inhalable pharmaceutical market. As chronic disorders continue to affect a considerable portion of the global population, the demand for effective and convenient treatment solutions such as inhalable pharmaceuticals rises, driving market expansion.
  • The growing healthcare infrastructure as well as increasing patient awareness, are boosting the inhalable medications industry. Improved healthcare facilities, such as modern inhalation devices and medication delivery systems, lead to improved inhalable drug accessibility and administration. Furthermore, improved patient awareness of the benefits of inhalable drugs leads to higher acceptance and market growth.
  • The development of inhalable formulations for the treatment of non-respiratory disorders, such as Parkinson's disease, can be attributed to the rise in the number of non-respiratory diseases driving the inhalable pharmaceutical industry. Inhalable drugs have benefits such as direct administration to the lungs, avoiding the digestive system, and potentially delivering faster onset and higher efficacy, making them appealing possibilities for non-respiratory disease therapy. This growing use of inhalable medications leads to market growth.
  • The boom in the production of inhalable drugs for simplicity of administration creates a sizable business opportunity. Non-invasive drug delivery, simple self-administration, and targeted drug delivery to the respiratory system are all advantages of inhalable medication formulations. The market for inhalable medications is expanding as pharmaceutical companies focus on developing user-friendly inhalation devices and enhancing drug formulations, catering to the need for easier and more accessible treatment choices.
  • A promising business opportunity exists in the growing reformulation of current non-inhaled compounds into inhaled molecules for enhanced drug delivery. The promise for improved pharmacological efficacy, faster onset of action, and less systemic adverse effects can be realized by converting existing pharmaceuticals into inhalable formulations. This strategy enables pharmaceutical companies to use their existing medication portfolios to develop novel inhalable medicines, thereby expanding the market and addressing unmet medical needs.
  • Strict rules for inhalable drug approval are a major market restraint. Before approving inhalable drugs, regulatory bodies demand extensive safety and efficacy data. Preclinical and clinical testing, comprehensive paperwork, and adherence to demanding quality standards are all part of the difficult clearance procedure. These limitations may cause delays and increased costs, hindering the expansion of the inhalable medicine business.
  • Unregulated and alternative therapies present a market challenge for inhalable drugs. Some people may choose unproven or alternative treatments over inhalable drugs. Due to a lack of regulation and scientific proof for these medicines, patients may seek alternative options, thereby affecting the adoption and market penetration of inhalable pharmaceuticals. To solve this difficulty, education and knowledge about the benefits of regulated drugs are required

Market Segmentations

  • The Global Inhalable Drugs Market is segmented based on Deployment Type, Solution Type, Fleet Size, End-User, and Geography.
  • By Product, the Global Inhalable Drugs Market is classified into Aerosol, Dry Powder Formulation, and Spray.
  • The Aerosol holds a significant market share. Because of their ability to give precise doses, convenience of use, and effective medication dispersion in the respiratory system, aerosols are commonly used and recommended for inhalable drugs.
  • By Application, the Global Inhalable Drugs Market is classified into Non-Respiratory Diseases and Respiratory Diseases.
  • Respiratory Diseases hold a larger market share. This is because inhalable drugs are primarily intended for treating respiratory disorders such as asthma, COPD, and allergies, which have a higher prevalence and demand for such prescriptions.
  • By Geography, the Global Inhalable Drugs Market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.
  • The Americas hold a significant market share. This can be caused by increased respiratory disease prevalence, well-established healthcare infrastructure, and advanced pharmaceutical industry in nations such as the United States and Canada.

Recent Development

  • Sanofi completes acquisition of Prevention Bio, Inc. - April 2023
  • Sanofi launches global health brand, to offer 30 meds on a non-profit basis - July 2022

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Adherium Ltd., AptarGroup, Inc., AstraZeneca PLC, Avalyn Pharma, Inc., Boehringer Ingelheim International GmbH, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxemburg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Nigeria, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Inhalable Drugs Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Inhalable Drugs Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Inhalable Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed Market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research0
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Rising Incidence of Respiratory Diseases Such as Chronic Obstructive Pulmonary Diseases and Asthma
4.2.2 Increasing Healthcare Infrastructure and Rising Awareness among Patients
4.2.3 Surge in the Number of Non-respiratory Diseases Such as Parkinson’s Disease
4.3 Restraints
4.3.1 Strict Regulations for the Approval of Inhalable Drugs
4.4 Opportunities
4.4.1 Surge in Development of Inhalable Drugs for Ease of Administration
4.4.2 Emerging Reformulation of Current Non-inhaled Molecules into Inhaled Molecules for Improved Drug Delivery
4.5 Challenges
4.5.1 Availability of Unregulated and Alternate Therapy
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Ansoff Matrix Analysis
6 Global Inhalable Drugs Market, By Product
6.1 Introduction
6.2 Aerosol
6.3 Dry Powder Formulation
6.4 Spray
7 Global Inhalable Drugs Market, By Application
7.1 Introduction
7.2 Non-Respiratory Diseases
7.3 Respiratory Diseases
8 America’s Inhalable Drugs Market
8.1 Introduction
8.2 Argentina
8.3 Brazil
8.4 Canada
8.5 Chile
8.6 Colombia
8.7 Mexico
8.8 Peru
8.9 United States
8.10 Rest of Americas
9 Europe's Inhalable Drugs Market
9.1 Introduction
9.2 Austria
9.3 Belgium
9.4 Denmark
9.5 Finland
9.6 France
9.7 Germany
9.8 Ireland
9.9 Italy
9.10 Luxembourg
9.11 Netherlands
9.12 Norway
9.13 Poland
9.14 Russia
9.15 Spain
9.16 Sweden
9.17 Switzerland
9.18 United Kingdom
9.19 Rest of Europe
10 Middle East and Africa's Inhalable Drugs Market
10.1 Introduction
10.2 Egypt
10.3 Israel
10.4 Qatar
10.5 Nigeria
10.6 Saudi Arabia
10.7 South Africa
10.8 United Arab Emirates
10.9 Rest of MEA
11 APAC's Inhalable Drugs Market
11.1 Introduction
11.2 Australia
11.3 Bangladesh
11.4 China
11.5 India
11.6 Indonesia
11.7 Japan
11.8 Malaysia
11.9 Philippines
11.10 Singapore
11.11 South Korea
11.12 Sri Lanka
11.13 Thailand
11.14 Taiwan
11.15 Rest of Asia-Pacific
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
13 Company Profiles
13.1 Adherium, Ltd.
13.1.1 Company Overview
13.1.2 Company Snapshot
13.1.3 Product Overview
13.1.4 Business Overview
13.1.5 SWOT Analysis
13.1.6 Recent Developments
13.2 AptarGroup, Inc.
13.2.1 Company Overview
13.2.2 Company Snapshot
13.2.3 Product Overview
13.2.4 Business Overview
13.2.5 SWOT Analysis
13.2.6 Recent Developments
13.3 AstraZeneca, PLC
13.3.1 Company Overview
13.3.2 Company Snapshot
13.3.3 Product Overview
13.3.4 Business Overview
13.3.5 SWOT Analysis
13.3.6 Recent Developments
13.4 Avalyn Pharma, Inc.
13.4.1 Company Overview
13.4.2 Company Snapshot
13.4.3 Product Overview
13.4.4 Business Overview
13.4.5 SWOT Analysis
13.4.6 Recent Developments
13.5 Boehringer Ingelheim International GmbH
13.5.1 Company Overview
13.5.2 Company Snapshot
13.5.3 Product Overview
13.5.4 Business Overview
13.5.5 SWOT Analysis
13.5.6 Recent Developments
13.6 Cipla, Inc.
13.6.1 Company Overview
13.6.2 Company Snapshot
13.6.3 Product Overview
13.6.4 Business Overview
13.6.5 SWOT Analysis
13.6.6 Recent Developments
13.7 GEA Group Ag
13.7.1 Company Overview
13.7.2 Company Snapshot
13.7.3 Product Overview
13.7.4 Business Overview
13.7.5 SWOT Analysis
13.7.6 Recent Developments
13.8 GSK, PLC
13.8.1 Company Overview
13.8.2 Company Snapshot
13.8.3 Product Overview
13.8.4 Business Overview
13.8.5 SWOT Analysis
13.8.6 Recent Developments
13.9 Merck & Co., Inc.
13.9.1 Company Overview
13.9.2 Company Snapshot
13.9.3 Product Overview
13.9.4 Business Overview
13.9.5 SWOT Analysis
13.9.6 Recent Developments
13.10 Mundipharma International, Ltd.
13.10.1 Company Overview
13.10.2 Company Snapshot
13.10.3 Product Overview
13.10.4 Business Overview
13.10.5 SWOT Analysis
13.10.6 Recent Developments
13.11 Novartis Ag
13.11.1 Company Overview
13.11.2 Company Snapshot
13.11.3 Product Overview
13.11.4 Business Overview
13.11.5 SWOT Analysis
13.11.6 Recent Developments
13.12 Orion Corp
13.12.1 Company Overview
13.12.2 Company Snapshot
13.12.3 Product Overview
13.12.4 Business Overview
13.12.5 SWOT Analysis
13.12.6 Recent Developments
13.13 Pfizer, Inc.
13.13.1 Company Overview
13.13.2 Company Snapshot
13.13.3 Product Overview
13.13.4 Business Overview
13.13.5 SWOT Analysis
13.13.6 Recent Developments
13.14 PureIMS B.V.
13.14.1 Company Overview
13.14.2 Company Snapshot
13.14.3 Product Overview
13.14.4 Business Overview
13.14.5 SWOT Analysis
13.14.6 Recent Developments
13.15 Respira Therapeutics, Inc.
13.15.1 Company Overview
13.15.2 Company Snapshot
13.15.3 Product Overview
13.15.4 Business Overview
13.15.5 SWOT Analysis
13.15.6 Recent Developments
13.16 Sanofi S.A.
13.16.1 Company Overview
13.16.2 Company Snapshot
13.16.3 Product Overview
13.16.4 Business Overview
13.16.5 SWOT Analysis
13.16.6 Recent Developments
13.17 Teva Pharmaceutical Industries, Ltd.
13.17.1 Company Overview
13.17.2 Company Snapshot
13.17.3 Product Overview
13.17.4 Business Overview
13.17.5 SWOT Analysis
13.17.6 Recent Developments
13.18 TFF Pharmaceuticals, Inc.
13.18.1 Company Overview
13.18.2 Company Snapshot
13.18.3 Product Overview
13.18.4 Business Overview
13.18.5 SWOT Analysis
13.18.6 Recent Developments
13.19 Vectura Group, Ltd.
13.19.1 Company Overview
13.19.2 Company Snapshot
13.19.3 Product Overview
13.19.4 Business Overview
13.19.5 SWOT Analysis
13.19.6 Recent Developments
13.20 Verona Pharma, PLC
13.20.1 Company Overview
13.20.2 Company Snapshot
13.20.3 Product Overview
13.20.4 Business Overview
13.20.5 SWOT Analysis
13.20.6 Recent Developments
14 Appendix
14.1 Self-Assessment Form

Companies Mentioned

  • Adherium, Ltd.
  • AptarGroup, Inc.
  • AstraZeneca, PLC
  • Avalyn Pharma, Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla, Inc.
  • GEA Group Ag
  • GSK, PLC
  • Merck & Co., Inc.
  • Mundipharma International, Ltd.
  • Novartis Ag
  • Orion Corp
  • Pfizer, Inc.
  • PureIMS B.V.
  • Respira Therapeutics, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries, Ltd.
  • TFF Pharmaceuticals, Inc.
  • Vectura Group, Ltd.
  • Verona Pharma, PLC